Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Mechanism of cell-free nucleic acid release and its utility as a cancer biomarker

EF 2018-19

Résumé
Cancer diagnosis often requires invasive tissue biopsy procedures that can be risky, painful, and costly. Non-invasive detection methods would make cancer diagnosis safer and more convenient and would allow for monitoring cancer during and after treatment. Since all cancer cells harbor alterations in their genetic material (DNA), detection of these alternations has clinical potential as a diagnostic tool. Free-floating DNA fragments in the bloodstream that is not associated with cells (cell-free DNA, cfDNA) can be used to detect cancer-specific alterations and could potentially be used to replace invasive biopsies. Since blood collection is relatively easy and can be done regularly, researchers aim to use cfDNA as a biomarker for cancer detection and treatment response monitoring. However, it is poorly understood how cfDNA is released into the bloodstream, limiting its clinical potential. Studies have identified multiple mechanisms of cfDNA release, and the relative contribution of each mechanism has been hotly debated. One such mechanism is via exosomes, which are small lipid structures released by cells that can also be found in the bloodstream. Due to the mounting interest in the use of exosomes as a source of cfDNA, there is an urgent need for rigorous study of the cfDNA content of exosomes and their potential as a cancer diagnostic tool. The objective of this proposed study is to investigate how much cfDNA is contained within exosomes in both cancer patients and healthy individuals. This work will resolve controversies in the field and reveal insights that can advance the use of cfDNA as a non-invasive biomarker to replace traditional biopsy.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406320
Name
Teng Mona
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Mechanism of cell-free nucleic acid release and its utility as a cancer biomarker
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Biomarker; Cancer Detection; Cell Free Dna; Disease Monitoring; Liquid Biopsy
Abstract
Cancer diagnosis often requires invasive tissue biopsy procedures that can be risky, painful, and costly. Non-invasive detection methods would make cancer diagnosis safer and more convenient and would allow for monitoring cancer during and after treatment. Since all cancer cells harbor alterations in their genetic material (DNA), detection of these alternations has clinical potential as a diagnostic tool. Free-floating DNA fragments in the bloodstream that is not associated with cells (cell-free DNA, cfDNA) can be used to detect cancer-specific alterations and could potentially be used to replace invasive biopsies. Since blood collection is relatively easy and can be done regularly, researchers aim to use cfDNA as a biomarker for cancer detection and treatment response monitoring. However, it is poorly understood how cfDNA is released into the bloodstream, limiting its clinical potential. Studies have identified multiple mechanisms of cfDNA release, and the relative contribution of each mechanism has been hotly debated. One such mechanism is via exosomes, which are small lipid structures released by cells that can also be found in the bloodstream. Due to the mounting interest in the use of exosomes as a source of cfDNA, there is an urgent need for rigorous study of the cfDNA content of exosomes and their potential as a cancer diagnostic tool. The objective of this proposed study is to investigate how much cfDNA is contained within exosomes in both cancer patients and healthy individuals. This work will resolve controversies in the field and reveal insights that can advance the use of cfDNA as a non-invasive biomarker to replace traditional biopsy.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Teng, Mona
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~